Vaccine Safety & Efficacy

The term "antibody adequacy" refers to an immunization's ability to provide the desired beneficial effects for those who have received it in a defined population when used in its ideal form. The potential risks of an adverse event following vaccination (AEFI) with that immunization must be weighed against the potential benefits of a successful immunization, such as improvement of wellbeing and prosperity, protection from illness and its physical, mental, and financial outcomes. The risk that a negative or unwanted outcome would occur, as well as the severity of the ensuing harm to the wellbeing of those who have received vaccinations in a defined population, after receiving an immunization in optimal usage conditions.

  • nfluenza Vaccines

  • Measles Vaccines

    Related Conference of Vaccine Safety & Efficacy

    May 30-31, 2024

    World congress on Immunology and Virology Diseases

    Vienna, Austria
    August 01-02, 2024

    44th Global Summit and Expo on Vaccines & Immunology

    Montreal, Canada
    September 09-10, 2024

    4th International Conference on Vaccine Research

    Madrid, Spain
    September 09-10, 2024

    7th International Conference on Vaccines and Immunology

    Madrid, Spain
    November 28-29, 2024

    6th World Congress on Vaccine and Immunology

    Paris, France

    Vaccine Safety & Efficacy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in